Hematocrit Test Market Is Currently Reached A Valuation Of Us$ 3 Billion In 2023 X Herald

(MENAFN- Ameliorate Digital Consultancy) By 2033, the market for hematocrit tests is expected to grow at a CAGR of 5% and reach US$ 4.9 billion.

The percentage of red blood cells in the blood is determined by a hematocrit test. It AIDS in determining the blood's ability to carry oxygen, level of hydration, and general state of health. The market for hematocrit testing is growing since cardiovascular diseases, certain cancers, and other ailments are becoming more common.

Download Free Sample Copy of This Report:

The demand for hematocrit tests is being driven by the rising prevalence of blood-related illnesses like anaemia, polycythemia, and haematological malignancies. certain tests help with the early recognition, diagnosis, and follow-up of certain illnesses, which results in successful treatment outcomes.

Anaemia is defined as a hematocrit level that is below the normal range, suggesting insufficient red blood cells. The hematocrit test is therefore crucial in the anaemia diagnosis. The increased incidence of anaemia is expected to increase demand for hematocrit assays.

The need for hematocrit testing is anticipated to rise as a result of government measures to raise anemia awareness. In 2021, to raise awareness of low hemoglobin levels in women and children, the Women and Child Development Department launched the Anemia Campaign 12. Thus, this will probably increase demand for hematocrit tests and assist in the expansion of the market.

Market expansion is being aided by rising awareness of preventative healthcare and regular health checkups. More and more people are taking proactive steps to monitor their blood health and spot any early-stage health issues. Haematology analyzers and point-of-care testing equipment have undergone technological developments that have increased the efficiency and accessibility of hematocrit assays. Automated analyzers deliver prompt and precise results, speeding up diagnosis and enhancing patient care.

Key Takeaways from Market Study

  • The global hematocrit test market is valued at US$ 3 billion in 2023.
  • Sales of hematocrit test devices are predicted to reach US$ 4.9 billion by 2033.
  • Worldwide demand for hematocrit test devices is forecasted to rise at a CAGR of 5% through 2033.
  • North America is leading the global market with 40% share in 2023.
  • Hematocrit test analyzers account for 50% share of overall sales in 2023.

Get Customization on this Report for Specific Research Solutions:

Key Segments of Hematocrit Test Industry Research

  • Mindray
  • Boule Diagnostics
  • Abbott
  • Roche
  • Siemens
  • Nihon Kohden
  • Bio-Rad Laboratories
  • Danaher
  • Horiba
  • Sysmex Corporation

Winning Strategy

The market for hematocrit tests is characterized by intense competition among key players offering a wide range of testing solutions. These companies strive to gain a competitive edge through product innovations, strategic partnerships, and expanding their geographical presence. Top market participants continually strive to introduce innovative solutions that enhance the accuracy, efficiency, and accessibility of hematocrit testing.

For instance,

  • PixCell Medical developed a portable point-of-care testing device called HemoScreenTM. This device employs patented viscoelastic focusing technology to deliver accurate hematocrit results within minutes using only a single drop of blood. The compact and user-friendly nature of HemoScreenTM makes it suitable for use in varisettings, including clinics, emergency rooms, and remote locations.

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the global hematocrit test market, presenting historical demand data (2018 to 2022) and forecast statistics for the period (2023 to 2033).

The study divulges essential insights on the hematocrit test market based on product (hematocrit test analyzers, hematocrit test meters, reagents & consumables, others), indication (anemia, leukemia, lymphoma, congenital heart diseases, kidney tumor), and end user (hospitals, clinics, diagnostic centers, others), across five major regions of the world (North America, Europe, Asia Pacific, Latin America, and MEA).

Sales Office :
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583


Ameliorate Digital Consultancy

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.